Literature DB >> 15654550

Secondary prevention after ischemic stroke. Evolution over time in practice.

Marie Girot1, Marie-Anne Mackowiak-Cordoliani, Dominique Deplanque, Hilde Hénon, Christian Lucas, Didier Leys.   

Abstract

BACKGROUND AND
OBJECTIVE: An optimal management of vascular risk factors, associated with antithrombotic drugs and carotid surgery when appropriate, reduces the risk of a new vascular event after stroke. Although secondary prevention is not optimal in many patients in practice, the question of whether there is an improvement over time remains unanswered. The aim of our study was to test the hypothesis that secondary prevention measures after cerebral ischemia improve over time.
METHOD: We included 123 consecutive patients in 1994, and 125 consecutive patients in 2002, who were admitted to a neurological department for any reason and had had an episode of cerebral ischemia less than 6 years earlier. We compared the groups for the management of arterial hypertension, hypercholesterolemia, diabetes mellitus and smoking. We recorded the values of blood pressure, biological parameters, and presence of antithrombotic therapy, lipid-lowering and anti-hypertensive drugs. Whether patients were properly treated or not, was determined by a comparison between their current treatment and guidelines available when recruited.
RESULTS: Prevention was not optimal in 96 of 123 (78%) patients in 1994, and in 77 of 125 (62 %) in 2002. Vascular risk factors were better identified and managed in 2002 than in 1994, especially for hypercholesterolemia. Antithrombotic therapies, statins and antihypertensive drugs, except calcium channel blockers, were more often used in 2002. The proportion of patients in whom arterial hypertension and hypercholesterolemia were identified was higher in 2002, but the proportion of patients identified as diabetics remained stable. However, the proportion of patients with blood pressure >140/90 mmHg, glycemia >or = 126 mg/dl, total cholesterol level > or = 240 mg/dl, or being current smokers, were significantly lower in 2002 than in 1994.
CONCLUSION: Although most of patients with previous cerebral ischemia did not receive an optimal management of their risk factors in 2002, there was an improvement over an 8-year period.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15654550     DOI: 10.1007/s00415-005-0591-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.

Authors: 
Journal:  Eur Heart J       Date:  1997-10       Impact factor: 29.983

2.  Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials.

Authors:  R Di Mascio; R Marchioli; G Tognoni
Journal:  Cerebrovasc Dis       Date:  2000 Mar-Apr       Impact factor: 2.762

Review 3.  Diabetes mellitus. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1985

4.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

5.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.

Authors: 
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

Review 6.  Cholesterol management in theory and practice.

Authors:  A M Gotto
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

7.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

8.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

9.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

10.  Risk factor modification in stroke prevention: the experience of a stroke clinic.

Authors:  L N Joseph; V L Babikian; N C Allen; M R Winter
Journal:  Stroke       Date:  1999-01       Impact factor: 7.914

View more
  8 in total

1.  Awareness, treatment, and control of vascular risk factors among stroke survivors.

Authors:  David A Brenner; Rich M Zweifler; Camilo R Gomez; Brett M Kissela; Deborah Levine; George Howard; Bruce Coull; Virginia J Howard
Journal:  J Stroke Cerebrovasc Dis       Date:  2010-05-15       Impact factor: 2.136

2.  Knowledge of stroke risk factors among primary care patients with previous stroke or TIA: a questionnaire study.

Authors:  Andrzej Sloma; Lars G Backlund; Lars-Erik Strender; Ylva Skånér
Journal:  BMC Fam Pract       Date:  2010-06-15       Impact factor: 2.497

3.  Intra-cerebral haemorrhages: are there any differences in baseline characteristics and intra-hospital mortality between hospitaland population-based registries?

Authors:  Charlotte Cordonnier; Matthieu P Rutgers; Frédéric Dumont; Marta Pasquini; Jean-Paul Lejeune; Delphine Garrigue; Yannick Béjot; Xavier Leclerc; Maurice Giroud; Didier Leys; Hilde Hénon
Journal:  J Neurol       Date:  2009-03-06       Impact factor: 4.849

4.  Risk awareness and knowledge of patients with stroke: results of a questionnaire survey 3 months after stroke.

Authors:  A Croquelois; J Bogousslavsky
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-20       Impact factor: 10.154

5.  Changes in pre-hospital management of vascular risk factors among patients admitted due to recurrent stroke in Poland from 1995 to 2013.

Authors:  Jan P Bembenek; Michał Karlinski; Iwona Kurkowska-Jastrzebska; Anna Czlonkowska
Journal:  Arch Med Sci       Date:  2016-07-01       Impact factor: 3.318

6.  Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.

Authors:  Nele Laleman; Séverine Henrard; Marjan van den Akker; Geert Goderis; Frank Buntinx; Gijs Van Pottelbergh; Bert Vaes
Journal:  BMC Cardiovasc Disord       Date:  2018-11-06       Impact factor: 2.298

7.  Risk awareness in secondary stroke prevention: a review of the literature.

Authors:  Julia Slark; Pankaj Sharma
Journal:  JRSM Cardiovasc Dis       Date:  2014-02-04

8.  Blood pressure after follow-up in a stroke prevention clinic.

Authors:  Agnete Hviid Hornnes; Mai Bang Poulsen
Journal:  Brain Behav       Date:  2020-06-12       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.